HK Stock Market Move | BEIGENE(06160) rose by over 4% again, is expected to achieve positive full-year operating profit this year.

BEIGENE (06160) rose more than 4%, up 4.15% as of the time of publication, trading at 123.1 Hong Kong dollars, with a turnover of 83.207 million Hong Kong dollars. On the news front, BEIGENE attended the 43rd annual J.P. Morgan Healthcare Conference on January 13 (Eastern US time) and made a presentation. CEO Mr. Olay strongly stated that the company expects to achieve positive operating profit for the full year 2025 under US GAAP (i.e. operating income exceeding the sum of operating costs, selling expenses, management expenses, and research and development expenses). Yuanta Securities International agrees with this outlook, citing the growth in sales of Brukinsa in the United States. The bank pointed out that BEIGENE's second-generation BTK drug Brukinsa is increasingly accepted by the market, gradually replacing AbbVie's Ibrutinib (Imbruvica). In addition, the company's prudent management of production costs and operational efficiency will further enhance profitability. The bank expects BEIGENE to achieve GAAP breakeven in 2025, as well as its first annual non-GAAP net profit.